Alisertib (MLN8237)

Catalog No.S1133

Alisertib (MLN8237) Chemical Structure

Molecular Weight(MW): 518.92

Alisertib (MLN8237) is a selective Aurora A inhibitor with IC50 of 1.2 nM in a cell-free assay. It has >200-fold higher selectivity for Aurora A than Aurora B. Phase 3.

Size Price Stock Quantity  
In DMSO USD 168 In stock
USD 120 In stock
USD 210 In stock
USD 670 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 48 Publications

12 Customer Reviews

  • Inhibition of Aurka kinase activity by MLN8237 impairs expression of pluripotency genes in CCE cells as measured by qRT-PCR. All values shown are mean ?SEM for n=3. The level of phosphorylated H3(S10) (p-H3(S10)), an Aurka phosphorylation target site, is decreased in MLN8237-treated samples.

    Cell Stem Cell 2012 11, 179-94. Alisertib (MLN8237) purchased from Selleck.

    Recruitment of clathrin to the mitotic spindle is controlled by phosphorylation of TACC3 by Aurora-A kinase. Representative micrographs of HEK293 cells incubated with 0.3 μM MLN8237 for 40 min. Cells were fixed and stained as indicated.

    EMBO J 2012 30, 906-19. Alisertib (MLN8237) purchased from Selleck.

  • Tissue levels of 53BP1, a-tubulin, IkB-a and IL-6 in an Hs294T xenograft treated with MLN8237 or vehicle control were visualized by immunofluorescence co-staining with DAPI. Representative micrographs are shown from triplicate experiments.

    EMBO Mol Med 2013 5(1), 149-66. Alisertib (MLN8237) purchased from Selleck.

    NUSAP mitotic phosphorylation at Ser 240 correlates with Aurora A activity. Protein samples of FLAG-NUSAP immunoprecipitated from I, M and MtMLN or with MtZM were analysed using LC-MS/MS, focusing on the predicted phosphorylated residue Ser 240. The histograms (A, B) show the calculated ratios based on peptides carrying the phosphorylated Ser 240 compared with all matched peptides containing this residue.

     

     

    EMBO reports 2010 11, 977-984. Alisertib (MLN8237) purchased from Selleck.

  • Aurora A inhibition rescues the PPP6C depletion phenotype. (A) HeLa cells transfected for 48 h with control and PPP6C si08 duplexes were treated with 10 or 20 nM MLN8237 or a solvent control for 15 min before lysis in phosphatase inhibitor containing buffer or fixation. Total lysates were analyzed by Western blotting. The red and black lines indicate the hosphorylated and nonphosphorylated forms of Aurora A. Fixed cells were stained using DAPI to detect DNA and antibodies to α-tubulin and Aurora A pT288. The intensity of pT288 staining was integrated using ImageJ over the spindle region defined by TPX2 staining and is plotted in the bar graph ( n = 4). Arrowheads indicate micronuclei. Bar, 5 µm. (B) HeLa cells transfected for 48 h with control and PPP6C si08 duplexes were treated with 10 nM MLN8237 or a solvent control for 24 h before fixation and staining with DAPI to detect DNA.

    J Cell Biol 2010 191, 1315-32. Alisertib (MLN8237) purchased from Selleck.

    D) Pharmacological inhibition of AURKA using alisertib led to downregulation of p-EIF4E (S209) and c-MYC proteins in FLO-1 and SK-GT-4 resistant cells, with or without RAD001 treatment.

    Clin Cancer Res, 2017, 23(14):3756-3768. Alisertib (MLN8237) purchased from Selleck.

  • Eg5 inhibition counteracts the induction of spindle pole fragmentation by Aurora-A inactivation. The protocol to inhibit Aurora-A by MLN8237 in cells progressing towards mitosis is depicted (time intervals not represented to scale). Control cultures were treated with solvent (DMSO) in the same time window. When indicated, MON was added 1 hour before harvesting. Note the absence of active phosphorylated (pThr288) Aurora-A (in red in IF panels) in cells treated with MLN8237. Upper histograms represent the percentage of all spindle and MT abnormalities in control and MLN8237-treated cultures (200 counted PM/M per condition in 2 experiments); the grey fraction of the histograms represents mitoses with spindle extrapoles, while other defects (monopolar or disorganised spindles, few and short MTs) are in white. Lower histograms and IF panels show that concomitant Eg5 inhibition by MON prevents MLN8237-induced spindle pole fragmentation (note the failure of centrosome migration reflecting Eg5 inactivation in lower IF panels). 200 PM/M per condition were counted in 2 experiments. Error bars represent s.d. **: p < 0.001, χ2 test. Red asterisks indicate significant differences with respect to DMSO controls, and black asterisks significant differences between Aurora-Ai mitoses with active or inactive Eg5. Scale bar: 10 μm

    Mol Cancer 2011 10, 131. Alisertib (MLN8237) purchased from Selleck.

    Alisertib inhibits AURKA and AURKB in a concentration-dependent manner. (a) Alisertib induces G 2 /M delay or genome reduplication. HeLa cells were exposed to buffer or the indicated concentrations of Alisertib. After 24 h, the cells were harvested and analyzed with flow cytometry. The positions of 2N, 4N and 8N DNA contents are indicated. (b) Alisertib delays mitotic exit or induces slippage. HeLa cells stably expressing histone H2B-GFP were exposed to buffer or the indicated concentrations of Alisertib. Individual cells were then tracked for 24 h with time-lapse microscopy. Each horizontal bar represents one cell (n ¼ 50). Key: light gray ¼ interphase; black ¼ mitosis (from DNA condensation to anaphase or mitotic slippage); dark gray ¼ interphase after mitotic slippage; truncated bars ¼ cell death. (c) Different concentrations of Alisertib are involved in delaying mitotic exit and inducing slippage. Live-cell imaging of cells treated with Alisertib was described in panel (b). The duration of mitosis (mean±90% confidence interval) and the percentage of cells that underwent mitotic slippage during the imaging period was quantified. (d) Alisertib promotes apoptosis in a concentration-dependent manner. HeLa cells were incubated with the indicated concentrations of Alisertib for 48 h. The cells were then harvested and analyzed with flow cytometry. (e) Concentration-dependent cytotoxicity of Alisertib. HeLa cells were cultured in the presence of the indicated concentrations of Alisertib for 48 h. The number of live and dead cells was analyzed with trypan blue exclusion assay. (f) Concentration-dependent suppression of long-term survival by Alisertib. HeLa cells were seeded on 60-mm culture plates and grown in the presence of 250 n M or 1 m M of Alisertib. After 24 h, the cells were washed gently and propagated in normal medium for another 10–12 days. Colonies were fixed and stained with crystal violet solution (examples of the plates are shown). Average±s.d. from three independent experiments. (g) Both AURKA and AURKB are inhibited by Alisertib.Mitotic HeLa cells were obtained by exposure to nocodazole for 16 h followed by mechanical shake off. The cells were incubated with the indicated concentrations of Alisertib for 2 h. Lysates were then prepared and activated phospho-AURKAThr288 and AURKBThr232were detected with immunoblotting. The asterisk indicates the position of an AURKB-like protein (the same throughout this study). Uniform loading was confirmed by immunoblotting for actin. In this assay, nocodazole and MG132 (a proteasome inhibitor) were added to prevent the cells from exiting mitosis. Accordingly, the total AURKA and AURKB levels remained constant throughout the experiment. (h) Alisertib prevents activation of AURKA and AURKB. HeLa cells were incubated with the indicated concentrations of Alisertib for 8 h. Nocodazole was then added for another 6 h to trap cells that entered mitosis. Lysates were prepared and analyzed with immunoblotting. Actin analysis was included to assess loading and transfer.

    Oncogene 2014 33, 3550-60. Alisertib (MLN8237) purchased from Selleck.

  • Inhibition of Aurora A (12.5 nM) by MLN8054 or MLN8237 was assessed in duplicate radiometric assays containing 100 μM [γ-32P] ATP and quantified by p81 phosphocellulose assay and scintillation counting. Kinase activity is reported as a percentage of control calculated from duplicate incubations containing 2.5% (v/v) DMSO. IC50 values represent the mean ±SEM calculated from two independent experiments.

     

     

    ACS Chem Biol 2010 5, 563-576. Alisertib (MLN8237) purchased from Selleck.

    The effects of T217D and T217N Aurora A mutations were directly compared to WT Aurora A-expressing cells. Each well was treated with either DMSO or 500 nM MLN8054 (E), or 30 nM MLN8237 (F) on day one of the experiment and cells were cultured for 8 days, at which point they were fixed. For all colony assays, an area encompassing >90 % of the colonies per dish is shown. Similar results were seen in two independent duplicate experiments.

    ACS Chem Biol 2010 5, 563-576. Alisertib (MLN8237) purchased from Selleck.

  • B, drug-treated cells were also stained with DAPI to visualize nuclear DNA and analyzed with a microscope equipped with a fluorescence digital CCD camera. Representative results are shown. Bar, 40 μm.

    J Biol Chem, 2017, 292(5):1910-1924. Alisertib (MLN8237) purchased from Selleck.

    C, Fry depletion decreases the level of Thr-210 phosphorylation of Plk1 on spindle poles. HeLa cells transfected with siRNAs were cultured in growth medium for 12 h and in thymidine-containing medium for 36 h. They were then released from thymidine arrest for 12 h before being fixed and stained with anti-Plk1 pT210 ( green) and anti-pericentrin (red) antibodies. DNA was stained with TO-PRO-3 ( blue ). For Aurora A inhibition, after release from thymidine block for 10 h, HeLa cells transfected with control siRNA were incubated for2h in medium containing MLN8237 (100 nM) and MG132 (10 μM). Magnified images of the white boxes are also shown. Scale bar ,5 μm.

    J Biol Chem 2012 287, 27670-81. Alisertib (MLN8237) purchased from Selleck.

Purity & Quality Control

Choose Selective Aurora Kinase Inhibitors

Biological Activity

Description Alisertib (MLN8237) is a selective Aurora A inhibitor with IC50 of 1.2 nM in a cell-free assay. It has >200-fold higher selectivity for Aurora A than Aurora B. Phase 3.
Features First orally available inhibitor of Aurora A.
Targets
Aurora A [1]
(Cell-free assay)
1.2 nM
In vitro

MLN8237 shows >200-fold higher selectivity for Aurora A than the structurally related Aurora B with an IC50 of 396.5 nM, and does not have any significant activity against 205 other kinases. [1] MLN8237 (0.5 μM) treatment inhibits the phosphorylation of Aurora A in MM1.S and OPM1 cells, without affecting the Aurora B mediated histone H3 phosphorylation. MLN8237 significantly inhibits cell proliferation in multiple myeloma (MM) cell lines with IC50 values of 0.003-1.71 μM. MLN8237 displays more potent anti-proliferation activity against primary MM cells and MM cell lines in the presence of BM stroma cells, as well as IL-6 and IGF-1 than against MM cells alone. MLN8237 (0.5 μM) induces 2- to 6-fold increase in G2/M phase in primary MM cells and cell lines, as well as significant apoptosis and senescence, involving the up-regulation of p53, p21 and p27, as well as PARP, caspase 3, and caspase 9 cleavage. In addition, MLN8237 shows strong synergistic anti-MM effect with dexamethasone, as well as additive effect with doxorubicin and bortezomib. [2] MLN8237 (0.5 μM) treatment causes the inhibition of colony formation of FLO-1, OE19, and OE33 esophageal adenocarinoma cell lines, and induces a significant increase in the percentage of polyploid cells, and subsequently an increase in the percentage of cells in the sub-G1 phase, which can be further enhanced in combination with cisplatin (2.5 μM), involving the higher induction of TAp73β, PUMA, NOXA, cleaved caspase-3, and cleaved PARP as compared with a single-agent treatment. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HCT116 NVWzWJR[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4TLT|AvPSEQvF2= MmeyO|IhcA>? NITieo9FVVOR M17vZ2lEPTB;MD6wOEDPxE1? MWqyOlE{PjZ6NB?=
LS174T MnvpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkPsNE42KM7:TR?= NGPZW2g4OiCq MlPpSG1UVw>? MoTwTWM2OD1yLkC1JO69VQ>? MYeyOlE{PjZ6NB?=
T84 NVq5fpA6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUXZ[WFXOC53IN88US=> NInEOVQ4OiCq MXnEUXNQ NFjhUHhKSzVyPUCuNFkh|ryP NYjPXZB5OjZzM{[2PFQ>
LS180 NIX0TnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUmwMlUh|ryP M{S0SlczKGh? M{DoO2ROW09? MnHCTWM2OD1zIN88US=> MUiyOlE{PjZ6NB?=
SW948 NEDBW5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVKwMlUh|ryP MV23NkBp MUPEUXNQ M17vNWlEPTB;MTFOwG0> M1TkSVI3OTN4Nki0
HCT15 NUGxOG9UT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWHGdmZyOC53IN88US=> MXm3NkBp NGDJZZFFVVOR M2\hVmlEPTB:MD60JO69VQ>? NX;QO|lPOjZzM{[2PFQ>
DLD-1 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2LZVVAvPSEQvF2= M17DVFczKGh? NFTKWIxFVVOR MkL2TWM2ODxyLkig{txO Mlv5NlYyOzZ4OES=
MIP-101 NGHC[ndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHPOZpIxNjVizszN MnWyO|IhcA>? M{i5XmROW09? NFnTOoJKSzVyPUGg{txO MmTsNlYyOzZ4OES=
SNU1544 NX:4eZR3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn\kNE42KM7:TR?= MVW3NkBp M2LwTmROW09? NWG4NnpqUUN3ME2xJO69VQ>? MYGyOlE{PjZ6NB?=
OCI-Ly10 MoPsR5l1d3SxeHnjJGF{e2G7 NXzZcJQ2PzJiaB?= M1nFfWROW09? NEm2RWhKSzVyPUCuNFU5KM7:TR?= NHTmWY0zPTh5OEOzNS=>
SU-DHL2 M2m4R2N6fG:2b4jpZ{BCe3OjeR?= M2m1[VczKGh? MlKwSG1UVw>? MWTJR|UxRTBwMEGg{txO NH\MSJIzPTh5OEOzNS=>
OCI-LY7 MVvDfZRwfG:6aXOgRZN{[Xl? M2jkUFczKGh? MoDISG1UVw>? M1TDdGlEPTB;MD6wPFEh|ryP M2nqdFI2QDd6M{Ox
SU-DHL6 NX3mNmJIS3m2b4TvfIlkKEG|c3H5 M3m2XFczKGh? MlHzSG1UVw>? NX3aNJBNUUN3ME2wMlQ5OiEQvF2= NIXRT3UzPTh5OEOzNS=>
Jeko-1 NGDzNYpEgXSxdH;4bYMhSXO|YYm= Mlz2O|IhcA>? M2PnTGROW09? M3njTWlEPTB;MD6wNlkh|ryP NF:5cJgzPTh5OEOzNS=>
JVM-2 MontR5l1d3SxeHnjJGF{e2G7 NVvwbZp[PzJiaB?= NFPnTFhFVVOR M{HS[WlEPTB;MD6wNUDPxE1? M1fDNFI2QDd6M{Ox
Rec-1 MX\DfZRwfG:6aXOgRZN{[Xl? Mn3MO|IhcA>? NWjp[HNbTE2VTx?= M1e2UmlEPTB;MD6wPFch|ryP M3rOdFI2QDd6M{Ox
Z-138 MoOxR5l1d3SxeHnjJGF{e2G7 M4nvclczKGh? NVHEZotQTE2VTx?= M{exRWlEPTB;MD6wNVMh|ryP MlP3NlU5Pzh|M{G=
H9 Mnr5R5l1d3SxeHnjJGF{e2G7 NH;SZoc4OiCq M2HJd2ROW09? MnP2TWM2OD1yLk[g{txO MlvVNlU5Pzh|M{G=
HH MX;DfZRwfG:6aXOgRZN{[Xl? NVznZ2VrPzJiaB?= NVjiblJVTE2VTx?= MXTJR|UxRTBwNzFOwG0> NVPNXJI5OjV6N{izN|E>
DND41 MWLDfZRwfG:6aXOgRZN{[Xl? NHfnUZg4OiCq MnXSSG1UVw>? NITYRoxKSzVyPUCuNUDPxE1? M{nXV|I2QDd6M{Ox
CCL119 MkfmR5l1d3SxeHnjJGF{e2G7 MYm3NkBp MVvEUXNQ MV;JR|UxRTBwME[yJO69VQ>? Mnr2NlU5Pzh|M{G=
J.Cam 1.6 MUXDfZRwfG:6aXOgRZN{[Xl? NYPOSopwPzJiaB?= MlPYSG1UVw>? NXiyUnFLUUN3ME2wMlExPSEQvF2= MVuyOVg4QDN|MR?=
Sup-T1 MXTDfZRwfG:6aXOgRZN{[Xl? NH3scHA4OiCq MUTEUXNQ NGLLR3RKSzVyPUKuNVQzKM7:TR?= MYWyOVg4QDN|MR?=
Tib 152 Moq3R5l1d3SxeHnjJGF{e2G7 MVu3NkBp M1\GN2ROW09? NH3RTHhKSzVyPUCuPEDPxE1? M2HhVVI2QDd6M{Ox
MCF7 MUjGeY5kfGmxbjDBd5NigQ>? NFnUeoY2KM7:TR?= NFvZPHEzPCCq MVfEUXNQ NF[1[JlKdmS3Y3XzJGczN01iYYLy[ZN1 M{jGeFI2QDN2NECx
MDA-MB-231 MmSzSpVv[3Srb36gRZN{[Xl? MVi1JO69VQ>? MYSyOEBp NWrYT5A1TE2VTx?= MWDJcoR2[2W|IFezM20h[XK{ZYP0 MUSyOVg{PDRyMR?=
MCF7 MUTGeY5kfGmxbjDBd5NigQ>? MWC1JO69VQ>? NYXBN441OjRiaB?= MY\EUXNQ M1HyNGRm[3KnYYPld{B1cGViZYjwdoV{e2mxbjDs[ZZmdCCxZjDDSGsyN0OGQ{K= NECwfHIzPTh|NESwNS=>
MCF7 MYHGeY5kfGmxbjDBd5NigQ>? NH7SOok2KM7:TR?= MoLkNlQhcA>? MorCSG1UVw>? MoXoSIVkemWjc3XzJJRp\SCneIDy[ZN{cW:wIHzleoVtKG:oIFPET|I> MUSyOVg{PDRyMR?=
MCF7 MVHGeY5kfGmxbjDBd5NigQ>? MkjsOUDPxE1? NX\G[2x{OjRiaB?= M3Xud2ROW09? MYXE[YNz\WG|ZYOgeIhmKGW6cILld5Nqd25ibHX2[Ywhd2ZiY4njcIlvKEJz M4Tib|I2QDN2NECx
MCF7 M2LHWGZ2dmO2aX;uJGF{e2G7 NFfLZ4Y2KM7:TR?= NHHYSnUzPCCq MmjCSG1UVw>? NVT0VoFjUW6lcnXhd4V{KHSqZTDlfJBz\XO|aX;uJIxmfmWuIH;mJJAzOSCZYX[xM2NqeDF? NXTjd|dLOjV6M{S0NFE>
MCF7 MnTQSpVv[3Srb36gRZN{[Xl? NVPMWmt6PSEQvF2= Mn\PNlQhcA>? M4DQOmROW09? M2\Ud2lv[3KnYYPld{B1cGViZYjwdoV{e2mxbjDs[ZZmdCCxZjDwNlchU2myMR?= M{[yc|I2QDN2NECx
MDA-MB-231 MnHvSpVv[3Srb36gRZN{[Xl? MkLuOUDPxE1? M1P3dFI1KGh? MYfEUXNQ Mn\3SIVkemWjc3XzJJRp\SCneIDy[ZN{cW:wIHzleoVtKG:oIFPET|EwS0SFMh?= NETq[m8zPTh|NESwNS=>
MDA-MB-231 M2f0fmZ2dmO2aX;uJGF{e2G7 MkfWNUDPxE1? NF;iUo8zPCCq M{jYTGROW09? M4S5SWlv[3KnYYPld{B1cGViZYjwdoV{e2mxbjDs[ZZmdCCxZjDDSGsz MV6yOVg{PDRyMR?=
MDA-MB-231 M3LiOWZ2dmO2aX;uJGF{e2G7 NWjN[lBvPSEQvF2= Moe4NlQhcA>? M17IcWROW09? MlrwSIVkemWjc3XzJJRp\SCneIDy[ZN{cW:wIHzleoVtKG:oIHP5Z4xqdiCEMR?= NVrUb4pWOjV6M{S0NFE>
MDA-MB-231 MWPGeY5kfGmxbjDBd5NigQ>? NV7qPHpFPSEQvF2= M1[wUVI1KGh? MnWySG1UVw>? M3f1Z2lv[3KnYYPld{B1cGViZYjwdoV{e2mxbjDs[ZZmdCCxZjDwNlEhX2GoMT;DbZAy NXzaTJU3OjV6M{S0NFE>
MDA-MB-231 NIXFWoZHfW6ldHnvckBCe3OjeR?= MX61JO69VQ>? MYiyOEBp NGjCb4VFVVOR MWLJcoNz\WG|ZYOgeIhmKGW6cILld5Nqd25ibHX2[Ywhd2ZicEK3JGtqeDF? MXWyOVg{PDRyMR?=
MDA-MB-231 M3foUmZ2dmO2aX;uJGF{e2G7 NVL1do1vPSEQvF2= NHHNVWQzPCCq MYPEUXNQ MV3JcoNz\WG|ZYOgeIhmKGW6cILld5Nqd25ibHX2[Ywhd2ZicEWz M13sO|I2QDN2NECx
MCF7 MX3BdI9xfG:|aYOgRZN{[Xl? MkPzOUDPxE1? NIfJdHozPCCq NGruNlRFVVOR MnzVTY5lfWOnczDhdI9xfG:2aXOg[IVifGh? NXP6NphoOjV6M{S0NFE>
MDA-MB-231 MVvBdI9xfG:|aYOgRZN{[Xl? NWfzRpUyPSEQvF2= NYCwVYtnOjRiaB?= M3rvOGROW09? NXO3SlNCUW6mdXPld{BieG:ydH;0bYMh\GWjdHi= NYHQUmNZOjV6M{S0NFE>
MCF7 NFvkeXhHfW6ldHnvckBCe3OjeR?= MVKxJO69VQ>? MX63NkBp MUDEUXNQ NXe0bYQ6UW6mdXPld{BifXSxcHjh[4lkKGSnYYTo Mn71NlU5OzR2MEG=
MDA-MB-231 NIPSdmVHfW6ldHnvckBCe3OjeR?= M4\KXVEh|ryP Ml;HO|IhcA>? MlPoSG1UVw>? M3fMbWlv\HWlZYOgZZV1d3CqYXfpZ{Bl\WG2aB?= Mo\5NlU5OzR2MEG=
U-2 OS MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYPTNldCPTBizszN Mk\pNlQhcA>? NGXzfIpFVVOR NGfEO2FKSzVyPUG2MlYh|ryP M3LPPFI2Pzl{OEGx
MG-63 NGCy[25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVW5RZV6PTBizszN NWG2UlNzOjRiaB?= NYPkWYdITE2VTx?= MYrJR|UxRTlwNTFOwG0> NGf6SZAzPTd7MkixNS=>
U-2 OS MmXqRZBweHSxc3nzJGF{e2G7 MYW1JO69VQ>? MkfFNlQhcA>? M3;XfWROW09? NVjhdVNvUW6mdXPld{BieG:ydH;0bYMh[2WubDDk[YF1cA>? NYHvUZRiOjV5OUK4NVE>
MG-63 NGjoRZNCeG:ydH;zbZMhSXO|YYm= NGS5flM2KM7:TR?= MVyyOEBp MV3EUXNQ MVXJcoR2[2W|IHHwc5B1d3SrYzDj[YxtKGSnYYTo NFzZNm0zPTd7MkixNS=>
U-2 OS NXv2VJlkTnWwY4Tpc44hSXO|YYm= M{f6VlUh|ryP MnP6NlQhcA>? NHOxNZFFVVOR NGnScWJRem:vb4Tld{BifXSxcHjh[4lkKGOnbHyg[IVifGh? MVmyOVc6OjhzMR?=
MG-63 MoriSpVv[3Srb36gRZN{[Xl? NIPOOpY2KM7:TR?= MmK3NlQhcA>? MWfEUXNQ NV24WnJjWHKxbX;0[ZMh[XW2b4DoZYdq[yClZXzsJIRm[XSq MorUNlU4QTJ6MUG=
PANC-1 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHTJVFE2OCEQvF2= MoT3NlQhcA>? NUHrfmdtTE2VTx?= M4TPeWlEPTB;Nz6xJO69VQ>? MkL2NlU3OzJ{MkW=
BxPC-3 Mnj6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoSzOVAh|ryP NGHu[ZQzPCCq MYrEUXNQ NUOzNWtlUUN3ME22Mlgh|ryP NHXle3YzPTZ|MkKyOS=>
PANC-1 NH22T5ZHfW6ldHnvckBCe3OjeR?= NHG1V5Y2KM7:TR?= NFPQcYczPCCq NH3PcItFVVOR Mn;BTY5lfWOnczDj[YxtKGO7Y3zlJIFzemW|dDDpckBIOi:PIIDoZZNm NETPPWIzPTZ|MkKyOS=>
BxPC-3 MV\GeY5kfGmxbjDBd5NigQ>? NF7lcoU2KM7:TR?= MYGyOEBp M4r1V2ROW09? NYXRfVd[UW6mdXPld{Bk\WyuIHP5Z4xmKGG{cnXzeEBqdiCJMj;NJJBp[XOn NXH5U|RnOjV4M{KyNlU>
PANC-1 NYLJd49jTnWwY4Tpc44hSXO|YYm= MYi1JO69VQ>? M135OFI1KGh? MW\EUXNQ MnjJTY5lfWOnczDheZRweGijZ3njJINmdGxiZHXheIg> MkjZNlU3OzJ{MkW=
BxPC-3 NGD5S25HfW6ldHnvckBCe3OjeR?= M1mzd|Uh|ryP M{H3Z|I1KGh? Mn33SG1UVw>? Mm\BTY5lfWOnczDheZRweGijZ3njJINmdGxiZHXheIg> NUj4dWU5OjV4M{KyNlU>
SKOV3 NEfyXVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWexNFAh|ryP NGj6dWEzPCCq NWr2SpA5TE2VTx?= NVLwU3dzUUN3ME2yNE41QCEQvF2= NFT5O|kzPTZ{NEe1NC=>
OVCAR4 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWG1e21EOTByIN88US=> NYjIboU3OjRiaB?= MlvySG1UVw>? NE\PN2VKSzVyPUKyMlE{KM7:TR?= M4fzNFI2PjJ2N{Ww
SKOV3 MYTGeY5kfGmxbjDBd5NigQ>? NEXEXoU2KM7:TR?= M4HMU|czKGh? MUnEUXNQ NFLBd|JKdmS3Y3XzJGczN01iYYLy[ZN1 NIXWPJEzPTZ{NEe1NC=>
OVCAR4 NXjRXmZXTnWwY4Tpc44hSXO|YYm= NI\MSZE2KM7:TR?= M3\WTFczKGh? M3W4dGROW09? M{WxUmlv\HWlZYOgS|IwVSCjcoLld5Q> NW\tSGt2OjV4MkS3OVA>
SKOV3 MX\BdI9xfG:|aYOgRZN{[Xl? MX61JO69VQ>? NWnoVIJLOjRiaB?= MXfEUXNQ M2nZVmlv\HWlZYOgZZBweHSxc3nz NGrFenMzPTZ{NEe1NC=>
OVCAR4 MmPXRZBweHSxc3nzJGF{e2G7 NV7XbWlmPSEQvF2= M1TOblI1KGh? NF\JelRFVVOR NX\wWJFPUW6mdXPld{BieG:ydH;zbZM> NHXDS5IzPTZ{NEe1NC=>
AGS MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoPpNlUh|ryP M2P3eFI1KGh? NGriSFRFVVOR MV7JR|UxRTF7LkC5JO69VQ>? M3HLfFI2PjB7OUKz
NCI-N78 NU\sRWlNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVLmeIp5OjVizszN M{\q[FI1KGh? MlnISG1UVw>? NIqyPWdKSzVyPUK2MlM{KM7:TR?= Mo\GNlU3ODl7MkO=
AGS MX7BdI9xfG:|aYOgRZN{[Xl? NVTnOGNtPSEQvF2= NUi3fIRGOjRiaB?= M3ryW2ROW09? M1X1NGlv\HWlZYOgZZBweHSxc3nz M4Dmd|I2PjB7OUKz
NCI-N78 MYTBdI9xfG:|aYOgRZN{[Xl? NWr0V45[PSEQvF2= Mn\UNlQhcA>? MYnEUXNQ M{[0Omlv\HWlZYOgZZBweHSxc3nz M1XBPFI2PjB7OUKz
AGS M3nTXmZ2dmO2aX;uJGF{e2G7 NHr6PHU2KM7:TR?= NYiwc5p[OjRiaB?= NYD0V5JKTE2VTx?= M3nvZmlv\HWlZYOgeIhmKGG3dH;wbIFogQ>? MnvyNlU3ODl7MkO=
NCI-N78 NUPDVIlxTnWwY4Tpc44hSXO|YYm= NXPYU4J5PSEQvF2= MnHxNlQhcA>? Mnj4SG1UVw>? MnLHTY5lfWOnczD0bIUh[XW2b4DoZYd6 NY\RRlNWOjV4MEm5NlM>
HSC-3 NXvCV|lIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVPVcJVpOSEQvF2= M2G1NVQ5KGh? MXPJR|UxRTBwNUSg{txO MmnrNlU{PjZzNEO=
GB30 M3jVOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIDFWVgyKM7:TR?= NUnKcFBzPyCm Mlm5SG1UVw>? M3XGXGlEPTB;MD6wNVEh|ryP M13tcVI2OTB4NEK4
GB9 M2fGWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUKxJO69VQ>? MnLjO{Bl MofOSG1UVw>? MknyTWM2OD1yLkCyOEDPxE1? NYnQbpFjOjVzME[0Nlg>
GB169 NV3GWG5OT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH;TcWoyKM7:TR?= MWW3JIQ> MXHEUXNQ MX3JR|UxRTBwMEOyJO69VQ>? NWnGOIIxOjVzME[0Nlg>
T24 MoOxSpVv[3Srb36gRZN{[Xl? M1\jclEh|ryP M{LSOVQ5KGh? MmDnSG1UVw>? MUTJcoR2[2W|IHPlcIwh[3mlbHWgZZJz\XO2 NXLy[Vk2OjN2MEO2N|M>
RT4 MnPFSpVv[3Srb36gRZN{[Xl? NHrVcWUyKM7:TR?= NGLaNJQ1QCCq NVzo[GhlTE2VTx?= NGjRNIhKdmS3Y3XzJINmdGxiY4njcIUh[XK{ZYP0 NH7Ld2MzOzRyM{[zNy=>
UM-UC-3 MknySpVv[3Srb36gRZN{[Xl? Mnu1NUDPxE1? M4HOelQ5KGh? MUDEUXNQ NWTQbnpKUW6mdXPld{Bk\WyuIHP5Z4xmKGG{cnXzeC=> NYPKbI1mOjN2MEO2N|M>
T24 Ml3MRZBweHSxc3nzJGF{e2G7 MkSyN{4yPiEQvF2= M{\Lflk3KGh? MY\EUXNQ MlmyTWM2OD1yLkCzNFYh|ryP MUWyN|QxOzZ|Mx?=
RT4 MVjBdI9xfG:|aYOgRZN{[Xl? MmDCN{4yPiEQvF2= NYjsPZNvQTZiaB?= NFzXbIRFVVOR M4S3TWlEPTB;MD6xNVk5KM7:TR?= MYqyN|QxOzZ|Mx?=
UM-UC-3 NXfo[IFQSXCxcITvd4l{KEG|c3H5 NXP1TYhXOy5zNjFOwG0> M1vp[lk3KGh? M2HRbmROW09? NXzPV|hpUUN3ME2wMlA1PDlizszN MYWyN|QxOzZ|Mx?=
OVCAR-5 MnTtSpVv[3Srb36gRZN{[Xl? MlTyOVAhdk1? NVrqfWZvUW6qaXLpeJMh[2WubDDtbYdz[XSrb36= Mk\ONlM{OzR|Mke=
SKOV3ip2 MX\GeY5kfGmxbjDBd5NigQ>? MUG1NEBvVQ>? M2fofGlvcGmkaYTzJINmdGxibXnndoF1cW:w M2jvNFI{OzN2M{K3
S462 Mn\WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVTHT5YzOTByIN88US=> MofrO|IhcA>? M2jrfmROW09? MoLKRZR1\W63YYTld{Bk\WyuIHfyc5d1cA>? NXniTIp[OjN|MkixNVQ>
2884 MlfSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYGxNFAh|ryP NVywbVZ2PzJiaB?= Ml21SG1UVw>? NEH4XGhCfHSnboXheIV{KGOnbHyg[5Jwf3Sq NWD3e286OjN|MkixNVQ>
2885 NHzaXmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFLafFYyODBizszN NHm0T204OiCq MWfEUXNQ Mo\zRZR1\W63YYTld{Bk\WyuIHfyc5d1cA>? MkfoNlM{OjhzMUS=
CRL-2396 M3jOR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlHqNVAxKM7:TR?= M33vTpdifGW{ M4G1TmlEPTB;MD6wPVIh|ryP MlTUNlMyPTN3MkS=
TIB-48 MlLBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWGxNFAh|ryP MljCe4F1\XJ? M2\VWWlEPTB;MD6wPFgh|ryP NXnhfIlUOjNzNUO1NlQ>
CRL-2396 M1ftXGN6fG:2b4jpZ{BCe3OjeR?= NE\Pd2QyKM7:TR?= Ml;SOFghcA>? NFXoU|d4[XSnch?= M3rhfGlv\HWlZYOgZZBweHSxc3nz MkK4NlMyPTN3MkS=
TIB-48 M1K2cmN6fG:2b4jpZ{BCe3OjeR?= MWCxJO69VQ>? M1ryO|Q5KGh? NX7SN|Fpf2G2ZYK= Moe3TY5lfWOnczDhdI9xfG:|aYO= MkDnNlMyPTN3MkS=
AGS NGPCb5hEgXSxdH;4bYMhSXO|YYm= MlTvNE42KM7:TR?= MoHyNlQhcA>? M2XNcGROW09? M3PWUGRm[3KnYYPld{Bk\WyuIIP1dpZqfmGu MWKyNlk4OjZzMR?=
FLO-1 MoDxR5l1d3SxeHnjJGF{e2G7 NEfhToUxNjVizszN NH61VI0zPCCq NEjZfJlFVVOR M{e1NWRm[3KnYYPld{Bk\WyuIIP1dpZqfmGu MX6yNlk4OjZzMR?=
OE33 NHS0UVhEgXSxdH;4bYMhSXO|YYm= MYiwMlUh|ryP M{OwVVI1KGh? NG\hTHVFVVOR NEHXcpJF\WO{ZXHz[ZMh[2WubDDzeZJ3cX[jbB?= MY[yNlk4OjZzMR?=
SKLMS NHLCZlREgXSxdH;4bYMhSXO|YYm= MYi3OUBvVQ>? MXm5OkBp M1ziNGlv\HWlZYOgZZBweHSxc3nz MWWyNlgzOTl7Nx?=
Leio285 M1XPRWN6fG:2b4jpZ{BCe3OjeR?= NGfnWFE4PSCwTR?= MW[5OkBp MVTJcoR2[2W|IHHwc5B1d3Orcx?= MmH3NlI5OjF7OUe=
Mes-Sa M2DJZ2N6fG:2b4jpZ{BCe3OjeR?= M2nSWVc2KG6P NVLqe|U6QTZiaB?= NIf5WIdKdmS3Y3XzJIFxd3C2b4Ppdy=> NVvFO4pSOjJ6MkG5PVc>
DAOY MmP2R5l1d3SxeHnjJGF{e2G7 MmHkNVAh|ryP MUm3NkBp MWnEUXNQ MnfpTWM2OD1yLkC0JO69VQ>? M33Ne|IzPjZ7M{O1
IMR32 M{L5RWN6fG:2b4jpZ{BCe3OjeR?= M3PabFExKM7:TR?= NXeycoVKPzJiaB?= NXyzWWdXTE2VTx?= MX\JR|UxRTBwMEOg{txO MkTzNlI3Pjl|M{W=
Molt-4 MUHDfZRwfG:6aXOgRZN{[Xl? MXmxNEDPxE1? MXm3NkBp NWH4OVFLTE2VTx?= MYrJR|UxRTBwMEKg{txO NYPUT3lZOjJ4NkmzN|U>
MOLM-13 M4foVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1H2UVMh|ryP MnjVO|IhcA>? NWOz[mNWTGmvaX7pd4hmeyClZXzsJJZq[WKrbHn0fS=> Mo\kNlI1QDh{NEm=
HL-60 NGL3fI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoPxN{DPxE1? NVXCNXJZPzJiaB?= NVHVV5JwTGmvaX7pd4hmeyClZXzsJJZq[WKrbHn0fS=> M2DVWFIzPDh6MkS5
MV4-11 MnrtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoDxN{DPxE1? NU\yWI95PzJiaB?= M4C3d2RqdWmwaYPo[ZMh[2WubDD2bYFjcWyrdIm= M1v2OFIzPDh6MkS5
SKM-1 NInr[IZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4PHOVMh|ryP NWDnRnYyPzJiaB?= Ml7uSIlucW6rc3jld{Bk\WyuII\pZYJqdGm2eR?= NGP0RmUzOjR6OEK0PS=>
SH2 MofES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn3TN{DPxE1? NGfCco04OiCq MWrEbY1qdmm|aHXzJINmdGxidnnhZoltcXS7 NXTS[Xl7OjJ2OEiyOFk>
NOMO-1 M2DkUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIiyO4g{KM7:TR?= NVzYXXUxPzJiaB?= M3jLdWRqdWmwaYPo[ZMh[2WubDD2bYFjcWyrdIm= MXSyNlQ5QDJ2OR?=
OCL-AML2 M4fQPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVyzJO69VQ>? MV:3NkBp NHnNOpJFcW2rbnnzbIV{KGOnbHygeoli[mmuaYT5 M4qxVVIzPDh6MkS5
PL-21 M1Ta[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVyzJO69VQ>? MlX6O|IhcA>? NH3HU4pFcW2rbnnzbIV{KGOnbHygeoli[mmuaYT5 M4XnelIzPDh6MkS5
KG-1 M{Xwd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHjCc4U{KM7:TR?= NHL6eZI4OiCq MYHEbY1qdmm|aHXzJINmdGxidnnhZoltcXS7 NE[yOVgzOjR6OEK0PS=>
A172 MX3DfZRwfG:6aXOgRZN{[Xl? NV\zeIUyOTByIN88US=> MYCyOEBp MVTEUXNQ MnjaTWM2OD1yLkGyNEDPxE1? M1TDfFIzOjd2M{m5
U87 MXrDfZRwfG:6aXOgRZN{[Xl? NWrsZ4hkOTByIN88US=> MknYNlQhcA>? M4LabmROW09? NVTmR2wzUUN3ME2wMlExPSEQvF2= NVS0cG5UOjJ{N{SzPVk>
U251 MmjFR5l1d3SxeHnjJGF{e2G7 M1ztfFExOCEQvF2= NY\ubnU4OjRiaB?= MWPEUXNQ MXPJR|UxRTBwMUCwJO69VQ>? M{HtXlIzOjd2M{m5
T98 NYrnd5NvS3m2b4TvfIlkKEG|c3H5 MUOxNFAh|ryP M{HFWFI1KGh? NXKz[Vl1TE2VTx?= Ml;tTWM2OD1yLkGyOUDPxE1? NU\GbmpSOjJ{N{SzPVk>
LN18 NIfBW|NEgXSxdH;4bYMhSXO|YYm= M{Hje|ExOCEQvF2= NE[xUnQzPCCq MXTEUXNQ NWPkUWplUUN3ME2wMlIyOCEQvF2= MmrYNlIzPzR|OUm=
LN443 NG\HWVlEgXSxdH;4bYMhSXO|YYm= MV6xNFAh|ryP NI\Ifo4zPCCq NHPEfGVFVVOR MmWwTWM2OD1yLkKyNEDPxE1? MkPsNlIzPzR|OUm=
HF66 NV3GbJU6S3m2b4TvfIlkKEG|c3H5 NEW3NWUyODBizszN MkTBNlQhcA>? MoTJSG1UVw>? MUDJR|UxRTBwMkK1JO69VQ>? M3HUW|IzOjd2M{m5
HF2303 Mkf2R5l1d3SxeHnjJGF{e2G7 MV:xNFAh|ryP M4TBW|I1KGh? NVjJU3FLTE2VTx?= NG\pNZpKSzVyPUCuNFYxKM7:TR?= MViyNlI4PDN7OR?=
HF2359 MmrJR5l1d3SxeHnjJGF{e2G7 MmK1NVAxKM7:TR?= NYr4Z21iOjRiaB?= MomwSG1UVw>? NFixRpJKSzVyPUCuNFYxKM7:TR?= NFv0O2YzOjJ5NEO5PS=>
HF2414 NV;IS3RqS3m2b4TvfIlkKEG|c3H5 NWj3OHQ4OTByIN88US=> MXGyOEBp M2P2[GROW09? NEXsOZFKSzVyPUCuNFgxKM7:TR?= M3XB[|IzOjd2M{m5
A-673 NV;3cHZ{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mlf4NVAh|ryP M33VO|k3KGh? NF24[XFFVVOR NGryNmNKSzVyPUCuNFMzKM7:TR?= Ml3GNlE1PDh3OUG=
TC-32 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYmxNEDPxE1? NWLjXZd{QTZiaB?= NUTZenBbTE2VTx?= MlfGTWM2OD1yLkCzPUDPxE1? M1LsSlIyPDR6NUmx
TC-71 NIn1bIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkLyNVAh|ryP MW[5OkBp NGf6[VFFVVOR NIDxUXRKSzVyPUCuNVAzKM7:TR?= NU\mOlczOjF2NEi1PVE>
SK-N-MC MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mm\NNVAh|ryP MVW5OkBp NX\MVZp4TE2VTx?= M1\rNGlEPTB;MD6wO|Ih|ryP MX2yNVQ1QDV7MR?=
CHLA-9 NEfS[nhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mmn6NVAh|ryP MUG5OkBp NIT1e|ZFVVOR MV;JR|UxRTBwMEG4JO69VQ>? MlOwNlE1PDh3OUG=
CHLA-10 NFzMdFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXmxNEDPxE1? MV[5OkBp NVPrRmJGTE2VTx?= NGHRc4lKSzVyPUCuNFYxKM7:TR?= NFfEN2UzOTR2OEW5NS=>
CHLA-25 M3X6[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MW[xNEDPxE1? NEnYRYE6PiCq MUXEUXNQ NIi3V5VKSzVyPUCuNVY5KM7:TR?= MYSyNVQ1QDV7MR?=
CHLA-32 Ml3TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYqxNEDPxE1? Mn;uPVYhcA>? MmXQSG1UVw>? NW\zUoZoUUN3ME2wMlE{PiEQvF2= MoTQNlE1PDh3OUG=
CHLA-56 NX25b3Y4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1qwbFExKM7:TR?= MmXoPVYhcA>? M4fHdmROW09? MXrJR|UxRTFyIN88US=> MXGyNVQ1QDV7MR?=
CHLA-258 NGPUd3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3;GblExKM7:TR?= NX2zSFNVQTZiaB?= MX;EUXNQ NIPCeXFKSzVyPUCuNVMzKM7:TR?= M4Xp[FIyPDR6NUmx
COG-E-352 M3\Sbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXixNEDPxE1? M3e1Slk3KGh? MlvTSG1UVw>? NEPHeW5KSzVyPUCuNFQ{KM7:TR?= Ml7HNlE1PDh3OUG=
CHLA-90 M4jZOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYSxNEDPxE1? MnPNPVYhcA>? MoLWSG1UVw>? NF7wV5lKSzVyPUCuNFYyKM7:TR?= Ml;5NlE1PDh3OUG=
CHLA-119 NXjB[3B5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXm5[oRvOTBizszN M1zOcVk3KGh? Mn;rSG1UVw>? MYXJR|UxRTBwMEKyJO69VQ>? Ml7DNlE1PDh3OUG=
CHLA-122 MorQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX:xNEDPxE1? MVS5OkBp NYHLW4NjTE2VTx?= M{O3OmlEPTB;MD6wNVkh|ryP MWCyNVQ1QDV7MR?=
CHLA-136 NFv1PY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2nW[|ExKM7:TR?= NEjtNHk6PiCq NHjlXHFFVVOR NVHVPVhGUUN3ME2wMlA{QSEQvF2= Mlj1NlE1PDh3OUG=
CHLA-140 NG[4N4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXy2OnlwOTBizszN NV;0TmRGQTZiaB?= NFPhVJZFVVOR M1viZmlEPTB;MD6wNlYh|ryP MWCyNVQ1QDV7MR?=
LA-N-6 Mlj6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MojPNVAh|ryP NHL0R3o6PiCq M{LBR2ROW09? NHmxT2FKSzVyPUCuNFU1KM7:TR?= MnnUNlE1PDh3OUG=
NB-1643 M2rhdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFG5fIkyOCEQvF2= M1XLRlk3KGh? MVrEUXNQ NWfUUYM2UUN3ME2wMlA{PyEQvF2= NHXCW|MzOTR2OEW5NS=>
NB-EBc1 M{XSUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIDCVpUyOCEQvF2= MUO5OkBp MkHjSG1UVw>? MXrJR|UxRTBwMEWwJO69VQ>? Ml:4NlE1PDh3OUG=
SK-N-BE-1 NWn5VnZTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH22N5EyOCEQvF2= NH7sV2o6PiCq Mm\iSG1UVw>? MVPJR|UxRTBwMEK4JO69VQ>? M334U|IyPDR6NUmx
SK-N-BE-2 NWq0ZpFzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mlm1NVAh|ryP NFfXeXE6PiCq M4L3WGROW09? M2LHSGlEPTB;MD6wN|Yh|ryP M3fVU|IyPDR6NUmx
SMS-KAN NYrZSZZLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NInRS2syOCEQvF2= M4fIS|k3KGh? NH3Z[GFFVVOR MULJR|UxRTBwMEO0JO69VQ>? M3vme|IyPDR6NUmx
SMS-KANR Mli0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFvve28yOCEQvF2= NE\PcoI6PiCq MYXEUXNQ MX;JR|UxRTBwMEK2JO69VQ>? NV7X[XprOjF2NEi1PVE>
SMS-KCN NG\jZ4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVGxNEDPxE1? MU[5OkBp NGHlToFFVVOR NWraPI8yUUN3ME2wMlAyQSEQvF2= NU\1ZmY3OjF2NEi1PVE>
SMS-KCNR NUTEOFdGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFzNWIMyOCEQvF2= M1nqSlk3KGh? NF;JR5FFVVOR Mki0TWM2OD1yLkCxNEDPxE1? MYOyNVQ1QDV7MR?=
SMS-LHN Mo\zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVyxNEDPxE1? MoXGPVYhcA>? MWrEUXNQ M1:0fGlEPTB;MD6wN|Ih|ryP M4rzUlIyPDR6NUmx
SMS-MSN M2HUemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkDCNVAh|ryP M4XSZ|k3KGh? NWHFSJB6TE2VTx?= NGq1VpdKSzVyPUCuNFIzKM7:TR?= NEPQdlczOTR2OEW5NS=>
SMS-SAN NHH6WGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M36zT|ExKM7:TR?= NEDPOYU6PiCq NIHI[29FVVOR Mon0TWM2OD1yLkCyNEDPxE1? MXqyNVQ1QDV7MR?=
Granta-4 NWrOUpBDS3m2b4TvfIlkKEG|c3H5 NFrSXG0yOCEQvF2= MXe3JIQ> MnfjTWM2OD1yLkC0NEDPxE1? NVHuTIROOjF{OUG4Olc>
DB M3foNGN6fG:2b4jpZ{BCe3OjeR?= M4fOdFExKM7:TR?= NWX5fVBmPyCm MkXZTWM2OD1yLkC0NkDPxE1? M3Pke|IyOjlzOE[3
RL M4\NVmN6fG:2b4jpZ{BCe3OjeR?= NHPwe2oyOCEQvF2= M174PVch\A>? MWLJR|UxRTBwMEG1JO69VQ>? M{TveVIyOjlzOE[3
K562 NFrVR5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVzHTll3OTBizszN M3jscFk3KGh? MV;JR|UxRTBwMEi3JO69VQ>? MWSyNVA6OTZ|Mx?=
LAMA-84 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXexNEDPxE1? NH7CbJI6PiCq MnmzTWM2OD1yLkC1O{DPxE1? MkT1NlExQTF4M{O=
MM15 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUG0JO69VQ>? M1XhflczKGh? MonlSG1UVw>? NXrIS2lmUUN3ME2wMlE{KM7:TR?= M1n0XFIxOzh{OES0
OPM1 NILG[|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYS0JO69VQ>? M3\B[|czKGh? MX\EUXNQ MkfWTWM2OD1yLkCzJO69VQ>? NEDWUIUzODN6Mki0OC=>
RPM1 NXXVS|J2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml6zOEDPxE1? M1:0XVczKGh? MXXEUXNQ MnXmTWM2OD1zMD6zNkDPxE1? MWGyNFM5Ojh2NB?=
INA6 MkfpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml62OEDPxE1? M4D4Z|czKGh? NXLZ[ZJCTE2VTx?= MnTyTWM2OD1yLkCwNkDPxE1? MVWyNFM5Ojh2NB?=
OPM2 M4jLdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{Pje|Qh|ryP NXXoeHk4PzJiaB?= NVfBW5JkTE2VTx?= MUTJR|UxRTRwM{eg{txO NF\Md|MzODN6Mki0OC=>
MM1R NGfBUWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mkn2OEDPxE1? NUTLeXNQPzJiaB?= NHjMXHhFVVOR NW\jepRLUUN3ME2xMlY5KM7:TR?= MmK0NlA{QDJ6NES=
DOX40 NY\vbJkyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV;0N2h[PCEQvF2= MYO3NkBp NX\DXFdMTE2VTx?= MnviTWM2OD13LkS4JO69VQ>? M1vJTVIxOzh{OES0
LR5 Mlv5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1fzNFQh|ryP MXK3NkBp MVvEUXNQ NInTd41KSzVyPUKuOVMh|ryP NY\0XnJ2OjB|OEK4OFQ>
U266 NVizOHJKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVu0JO69VQ>? MUi3NkBp M2XuNWROW09? MWfJR|UxRTFwNEOg{txO M{H3blIxOzh{OES0
RD NXjzNnJ{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3\2UlExKM7:TR?= NVS2Ooc4QTZiaB?= NGf3OZJKSzVyPUCuNlI5KM7:TR?= MmS3NlAyODh|M{i=
Rh41 M364RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV[xNEDPxE1? MYW5OkBp MWTJR|UxRTBwMEmwJO69VQ>? M1vpN|IxOTB6M{O4
Rh30 NIrUe|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MorSNVAh|ryP MVK5OkBp NGjC[XZKSzVyPUCuNlMxKM7:TR?= MUCyNFExQDN|OB?=
BT-12 MnS1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWDQTnpNOTBizszN MUK5OkBp NE\U[ppKSzVyPUCuNFYxKM7:TR?= MYmyNFExQDN|OB?=
CHLA-266 M2H3Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXzFcJhEOTBizszN MVO5OkBp NGLOXIxKSzVyPUCuNFczKM7:TR?= M3[0fFIxOTB6M{O4
TC-71 M17PXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUWxNEDPxE1? NXvTN45kQTZiaB?= Mlz3TWM2OD1yLkGwNkDPxE1? NVjw[pNNOjBzMEizN|g>
SJ-GBM2 M2nsRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnrXNVAh|ryP NHPm[Jk6PiCq MnzITWM2OD1yLkC1NEDPxE1? NYT0NolSOjBzMEizN|g>
NALM-6 NH3pfY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoHBNVAh|ryP MlXiPVYhcA>? NWq0PWRiUUN3ME2wMlA3OiEQvF2= M{fPNVIxOTB6M{O4
COG-LL-317 M3Tpemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV\wdJNbOTBizszN Mmq0PVYhcA>? MYrJR|UxRTBwMES3JO69VQ>? MkjDNlAyODh|M{i=
RS4-11 M3HVOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYSxNEDPxE1? M2m5dlk3KGh? MYjJR|UxRTBwMEG4JO69VQ>? MYOyNFExQDN|OB?=
MOLT-4 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFnBbnEyOCEQvF2= MYW5OkBp NUfNUpBZUUN3ME2wMlAzPiEQvF2= Mo[xNlAyODh|M{i=
CCRF-CEM NFfCN3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVixNEDPxE1? M125Slk3KGh? NUKyVZhVUUN3ME2wMlA6PCEQvF2= MV:yNFExQDN|OB?=
Kasumi-1 NWj4bHg4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFv3T|gyOCEQvF2= NVfI[Gt2QTZiaB?= NWjCUHBsUUN3ME2wMlExOyEQvF2= MXOyNFExQDN|OB?=
Karpas-299 NY\ZWmFbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUmxNEDPxE1? MmezPVYhcA>? MX\JR|UxRTBwMEO4JO69VQ>? NUXafndGOjBzMEizN|g>
Ramos-RA1 NF\2TWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV7Hd3JOOTBizszN NIqxZmc6PiCq NHjN[ldKSzVyPUCuNVI4KM7:TR?= M1;BNlIxOTB6M{O4

... Click to View More Cell Line Experimental Data

In vivo MLN8237 significantly reduces the tumor burden with tumor growth inhibition (TGI) of 42% and 80% at 15 mg/kg and 30 mg/kg, respectively, and prolongs the survival of mice compared with the control. [2]

Protocol

Kinase Assay:[1]
+ Expand

Aurora A radioactive Flashplate enzyme assay:

Aurora A radioactive Flashplate enzyme assay is conducted to determine the nature and degree of MLN8237-mediated inhibition in vitro. Recombinant Aurora A is expressed in Sf9 cells and purified with GST affinity chromatography. The peptide substrate for Aurora A is conjugated with biotin (Biotin-GLRRASLG). Aurora A kinase (5 nM) is assayed in 50 mM Hepes (pH 7.5), 10 mM MgCl2, 5 mM DTT, 0.05% Tween 20, 2 μM peptide substrate, 3.3 μCi/mL [γ-33P]ATP at 2 μM, and increasing concentrations of MLN8237 by using Image FlashPlates.
Cell Research:[2]
+ Expand
  • Cell lines: MM1.S, MM.1R, LR5, RPMI 8226, DOX40, OPM1, OPM2, INA6, and U266
  • Concentrations: Dissolved in DMSO, final concentrations ~10 μM
  • Incubation Time: 24, 48, and 72 hours
  • Method: Cells are exposed to various concentrations of MLN8237 for 24, 48, and 72 hours. Cells viability is measured using MTT assay, and cell proliferation is measured using 3[H]-thymidine incorporation. For cell cycle analysis, cells are permeabilized by 70% ethanol at -20 °C, and incubated with 50 μg/mL PI and 20 units/mL RNase-A. DNA content is analyzed by flow cytometry using BDFACS-Canto II and FlowJo software. For the detection of apoptosis and senescence, cells are stained with fluorescein isothiocyanate-annexin V and PI. Apoptotic cells are determined by flow cytometric analysis using BDFACS-Canto II and FlowJo software.
    (Only for Reference)
Animal Research:[2]
+ Expand
  • Animal Models: Severe combined immune-deficient (SCID) mice inoculated subcutaneously with MM1.S cells
  • Formulation: Formulated in 10% 2-hydroxypropyl-β-cyclodextrin/1% sodium bicarbonate
  • Dosages: ~30 mg/kg/day
  • Administration: Orally
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 27 mg/mL (52.03 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5%DMSO+30% PEG300+5%Tween-80+ddH2O
For best results, use promptly after mixing.
8mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 518.92
Formula

C27H20ClFN4O4

CAS No. 1028486-01-2
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01924260 Active not recruiting Acinar Cell Adenocarcinoma of the Pancreas|Duct Cell Adenocarcinoma of the Pancreas|Recurrent Pancreatic Cancer|Stage III Pancreatic Cancer|Stage IV Pancreatic Cancer|Unspecified Adult Solid Tumor Protocol Specific University of California Davis|National Cancer Institute (NCI)|Takeda August 9 2013 Phase 1
NCT01397825 Completed Diffuse Large B-Cell Lymphoma|Transformed Follicular Lymphoma|Mantle Cell Lymphoma|Burkitt''s Lymphoma Millennium Pharmaceuticals Inc.|Takeda August 9 2011 Phase 1|Phase 2
NCT01677559 Completed Adenocarcinoma|Pancreatic Neoplasms Washington University School of Medicine May 7 2013 Phase 1
NCT00697346 Completed B-cell Follicular Lymphoma|B-cell Marginal Zone Lymphoma|Diffuse Large B-cell Lymphoma|B-cell Mantle Cell Lymphoma|B-cell Small Lymphocytic Lymphoma (SLL)|B-Cell Chronic Lymphocytic Leukemia (B-CLL)|Multiple Myeloma|Waldenstrom''s Macroglobulinemia|Noncutaneous Peripheral T-cell Lymphoma Not Otherwise Specified (PTCL-NOS)|Angioimmunoblastic T-cell Lymphoma (AITL)|Anaplastic Large Cell Lymphoma|Enteropathy Associated T-cell Lymphoma (EATCL)|NK Lymphoma (NKL) Millennium Pharmaceuticals Inc.|Takeda October 7 2008 Phase 1
NCT02860000 Recruiting Estrogen Receptor Status|HER2/Neu Negative|Invasive Breast Carcinoma|Postmenopausal|Stage III Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer|Stage IV Breast Cancer Mayo Clinic|National Cancer Institute (NCI) July 6 2017 Phase 2
NCT02219789 Completed Estrogen Receptor Positive|Progesterone Receptor Positive|Recurrent Breast Carcinoma|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer|Stage IV Breast Cancer Mayo Clinic|National Cancer Institute (NCI) December 5 2014 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    What is the suggested formulation of this compound for mouse injection(i.p.)?

  • Answer:

    It can be dissolved in 6% DMSO/50% PEG 300/5% Tween 80/ddH2O at 10 mg/ml as a clear solution.

Aurora Kinase Signaling Pathway Map

Aurora Kinase Inhibitors with Unique Features

Related Aurora Kinase Products

Tags: buy Alisertib (MLN8237) | Alisertib (MLN8237) supplier | purchase Alisertib (MLN8237) | Alisertib (MLN8237) cost | Alisertib (MLN8237) manufacturer | order Alisertib (MLN8237) | Alisertib (MLN8237) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID